Gerald, I agree with your view. In the short term, say 6-12 months, the relevant release is:
aviron.com
Success in the study mentioned in biz.yahoo.com
has direct implications for public health policy and, thus, ultimate market size, not necessarily for approval. Certainly the company is not waiting for completion of this study before going to the FDA. They feel, as per the first link above, that they have generated enough positive data to have the vaccine in the market. The relevant speculation here, especially from a trading view point, is whether approval would come in time for the 98-99 flu season, or if we'll have to wait for the 99-00 season.
PB |
